Dr. Lal Pathlabs Limited — Earnings Release 2020

Aug 13, 2019

==> picture [24 x 39] intentionally omitted <==

==> picture [254 x 29] intentionally omitted <==

August 13, 2019

The National Stock Exchange of India Limited Exchange Plaza Sandra Kurla Complex, Sandra (E) Mumbai - 400051

The Bombay Stock Exchange Limited 15[th ] Floor, Phiroze Jeejeeboy Towers Dalal Street, Mumbai - 400001

Subject: Press Release for Unaudited Financial Results (Standalone and Consolidated) for the Quarter ended June 30, 2019

Dear Sir/Madam,

Please find enclosed herewith the Press Release for the Unaudited Financial Results (Standalone and Consolidated) for the Quarter ended June 30, 2019.

You are requested to take note of the above.

Thanking You,

Yours Faithfully,

==> picture [188 x 97] intentionally omitted <==

Encl: As above

Regd. Office: Dr. Lal Pdlhlahs Ltd .. B[1] nck E, SeClnr-18, Rolmri, l�,:w Delhi - ! !OOt>S, +91-11-302'.;8,'.,00. Fax: +91-1 J-2�68-2134 Corpor;ate Office: Dr. Lal PalhLabs L:d • ! 2th F!u<Jr, Tower B, SAS Tower, M�cfo•ity, <,-:tor-30, Guru,yam - l 22 00 I, Haryana +91-124-30 J 6-sno Fax: +91-I 24-4234-4l E-mail· 1aJpathJ�t·"•01alpi 1;,hs rc,m. Web: wwv '.'.alf'-"ll" ,>h< rom, CIN No.: LH v ,'tDL i 'i 6PLCG·�52SS

==> picture [150 x 35] intentionally omitted <==

==> picture [79 x 9] intentionally omitted <==

----- Start of picture text ----- August 13, 2019----- End of picture text -----

For Immediate Release August 13, 2019 Dr. Lal PathLabs Limited records revenue growth of 14.7% to Rs 335.2 Cr in Q1 FY2019-20

New Delhi, India, Aug 13, 2019 – Dr. Lal PathLabs Limited (referred to as the “Company”; NSE: LALPATHLAB, BSE: 539524), a leading diagnostic and related healthcare service provider announces their financial results for the quarter ended June 30, 2019

Consolidated Performance Highlights: Q1FY2019-20 vs Q1FY2018-19 Revenue growth: 14.7% at Rs 335.2 Cr, Normalised EBITDA ex Ind AS 116 at Rs 90.8 Cr, Normalised EBITDA margins ex Ind AS 116 at 27.1%, PBT at Rs 89.4 Cr and PAT Rs 59.1 Cr with margin at 17.6%

• Operating Revenue increased by 14.7% in Q1 FY 20 to Rs. 335.2 Cr vs Rs 2,92.3 Cr in the previous year same quarter. Underlying volume growth is 15.9% during the quarter

• Normalised EBITDA (after adjustment for stock based compensation, CSR cost & impact of Ind AS 116) for Q1FY20 grew 14.5 % to Rs. 90.8 Cr from Rs 79.3 Cr in the same quarter last year

• Normalised EBITDA Margin ex Ind AS 116 at 27.1% for Q1 FY20

• PBT is at Rs 89.4 Cr in Q1 FY20 vs Rs 75.4 Cr. in Q1 last year, a growth of 18.6%

• Profit after Tax in Q1 FY20 at Rs. 59.1 Cr as compared to Rs 49.7 Cr in Q1 last year, a growth of 19.0%

Financial Overview (Consolidated) in Rs Cr

==> picture [462 x 199] intentionally omitted <==

----- Start of picture text ----- Q1 FY20 Q1 FY20 Q1 FY19 Gr % Gr %Particulars (With IND-AS (W/O IND-AS (W/O IND-AS (Respective (W/O IND-AS116) 116) 116) AS) 116)Revenue 335.2 335.2 292.3 14.7% 14.7%Expenditure 240.1 248.3 217.3EBITDA 95.1 86.9 75.0 26.8% 15.9%Adj for Stock based comp. & CSR cost 3.9 3.9 4.3Normalised EBITDA 99.0 90.8 79.3 24.9% 14.5%Normalised Margins 29.5% 27.1% 27.1%Other income incl. interest 14.4 14.4 9.4PBT 89.4 91.9 75.4 18.6% 21.9%Margins 26.7% 27.4% 25.8%PAT 59.1 60.7 49.7 19.0% 22.2%Margins 17.6% 18.1% 17.0%EPS (Basic) 7.14 6.00 19.0%EPS (Diluted) 7.13 6.00 18.8%----- End of picture text -----

Dr. Lal Pathlabs Limited 12[th] Floor, Tower-B, SAS Tower, Sector-38, Medicity, Gurgaon 122001, Phone: +91 124 3016500, website: www.lalpathlabs.com

1

==> picture [150 x 35] intentionally omitted <==

About Dr. Lal PathLabs Limited

Dr. Lal PathLabs is a provider of diagnostic and related healthcare tests and services in India. Through its integrated, nationwide network, the company offer patients and healthcare providers a broad range of diagnostic and related healthcare tests and services for use in core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions.

As on March 31, 2019 the company has 200 clinical laboratories (including National Reference Lab at Delhi & Regional Reference Lab at Kolkata), 2,569 Patient Service Centers (PSCs) and 6,426 Pick-up Points (PUPs). It’s customers include individual patients, hospitals and other healthcare providers and corporate customers.

Contact Details

Ved Prakash Goel +91 124 3016500 Chief Financial Officer cfo@lalpathlabs.com Dr. Lal PathLabs Limited +91 9811177405 Aparna Agarwal aparna.agarwal@adfactorspr.com Adfactors PR

For further information on Dr. Lal PathLabs see www.lalpathlabs.com

Safe Harbour

This release contains statements that contain “forward looking statements” including, but without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to Dr. Lal PathLabs future business developments and economic performance. While these forward looking statements indicate our assessment and future expectations concerning the development of our business, a number of risks, uncertainties and other unknown factors could cause actual developments and results to differ materially from our expectations. These factors include, but are not limited to, general market, macro-economic, governmental and regulatory trends, movements in currency exchange and interest rates, competitive pressures, technological developments, changes in the financial conditions of third parties dealing with us, legislative developments, and other key factors that could affect our business and financial performance. Dr. Lal PathLabs undertakes no obligation to publicly revise any forward looking statements to reflect future / likely events or circumstances.

Dr. Lal Pathlabs Limited

12[th] Floor, Tower-B, SAS Tower, Sector-38, Medicity, Gurgaon 122001, Phone: +91 124 3016500, website: www.lalpathlabs.com

2